Logo image of CYTO

ALTAMIRA THERAPEUTICS LTD (CYTO) Stock Fundamental Analysis

NASDAQ:CYTO - Nasdaq - BMG0360L1349 - Common Stock - Currency: USD

0.3  -0.11 (-25.94%)

After market: 0.262 -0.04 (-12.67%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to CYTO. CYTO was compared to 198 industry peers in the Pharmaceuticals industry. The financial health of CYTO is average, but there are quite some concerns on its profitability. CYTO has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

CYTO had positive earnings in the past year.
CYTO had a positive operating cash flow in the past year.
In the past 5 years CYTO always reported negative net income.
In the past 5 years CYTO always reported negative operating cash flow.
CYTO Yearly Net Income VS EBIT VS OCF VS FCFCYTO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

Looking at the Return On Assets, with a value of -0.09%, CYTO belongs to the top of the industry, outperforming 82.20% of the companies in the same industry.
With an excellent Return On Equity value of -0.11%, CYTO belongs to the best of the industry, outperforming 82.72% of the companies in the same industry.
Industry RankSector Rank
ROA -0.09%
ROE -0.11%
ROIC N/A
ROA(3y)-179.21%
ROA(5y)-129.77%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CYTO Yearly ROA, ROE, ROICCYTO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500 1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CYTO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CYTO Yearly Profit, Operating, Gross MarginsCYTO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5K -10K -15K -20K -25K

More info and screens

4

2. Health

2.1 Basic Checks

CYTO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CYTO has more shares outstanding
The number of shares outstanding for CYTO has been increased compared to 5 years ago.
Compared to 1 year ago, CYTO has an improved debt to assets ratio.
CYTO Yearly Shares OutstandingCYTO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 500K 1M
CYTO Yearly Total Debt VS Total AssetsCYTO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of 1.19, we must say that CYTO is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of CYTO (1.19) is better than 60.21% of its industry peers.
The Debt to FCF ratio of CYTO is 0.09, which is an excellent value as it means it would take CYTO, only 0.09 years of fcf income to pay off all of its debts.
CYTO has a Debt to FCF ratio of 0.09. This is amongst the best in the industry. CYTO outperforms 96.86% of its industry peers.
CYTO has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
CYTO has a Debt to Equity ratio (0.05) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF 0.09
Altman-Z 1.19
ROIC/WACCN/A
WACC7.3%
CYTO Yearly LT Debt VS Equity VS FCFCYTO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M

2.3 Liquidity

CYTO has a Current Ratio of 0.43. This is a bad value and indicates that CYTO is not financially healthy enough and could expect problems in meeting its short term obligations.
CYTO has a Current ratio of 0.43. This is amonst the worse of the industry: CYTO underperforms 95.81% of its industry peers.
CYTO has a Quick Ratio of 0.43. This is a bad value and indicates that CYTO is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.43, CYTO is doing worse than 95.29% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.43
Quick Ratio 0.43
CYTO Yearly Current Assets VS Current LiabilitesCYTO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 101.44% over the past year.
The Revenue for CYTO has decreased by -79.76% in the past year. This is quite bad
EPS 1Y (TTM)101.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.56%
Revenue 1Y (TTM)-79.76%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

CYTO is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -4.65% yearly.
The Revenue is expected to grow by 214.13% on average over the next years. This is a very strong growth
EPS Next Y-88.67%
EPS Next 2Y8.03%
EPS Next 3Y-4.65%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y214.13%
Revenue Next 5YN/A

3.3 Evolution

CYTO Yearly Revenue VS EstimatesCYTO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2026 1M 2M 3M 4M 5M
CYTO Yearly EPS VS EstimatesCYTO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2018 2019 2024 2025 2026 -1K -2K -3K -4K

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

CYTO is valuated cheaply with a Price/Earnings ratio of 0.36.
Based on the Price/Earnings ratio, CYTO is valued cheaply inside the industry as 99.48% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of CYTO to the average of the S&P500 Index (28.92), we can say CYTO is valued rather cheaply.
CYTO is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 0.36
Fwd PE N/A
CYTO Price Earnings VS Forward Price EarningsCYTO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, CYTO is valued cheaper than 100.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 0.25
EV/EBITDA N/A
CYTO Per share dataCYTO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 1.5

4.3 Compensation for Growth

CYTO's earnings are expected to decrease with -4.65% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.03%
EPS Next 3Y-4.65%

More info and screens

0

5. Dividend

5.1 Amount

CYTO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALTAMIRA THERAPEUTICS LTD

NASDAQ:CYTO (12/19/2024, 10:21:17 PM)

After market: 0.262 -0.04 (-12.67%)

0.3

-0.11 (-25.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)09-10 2024-09-10
Earnings (Next)N/A N/A
Inst Owners0.13%
Inst Owner Change0%
Ins Owners0.53%
Ins Owner ChangeN/A
Market Cap1.13M
Analysts82.86
Price Target5.41 (1703.33%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-35.44%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)31.88%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 0.36
Fwd PE N/A
P/S 18.07
P/FCF 0.25
P/OCF 0.25
P/B 0.18
P/tB 0.67
EV/EBITDA N/A
EPS(TTM)0.83
EY276.67%
EPS(NY)-1.19
Fwd EYN/A
FCF(TTM)1.22
FCFY406.8%
OCF(TTM)1.22
OCFY406.8%
SpS0.02
BVpS1.67
TBVpS0.45
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -0.09%
ROE -0.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM 7351.86%
ROA(3y)-179.21%
ROA(5y)-129.77%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF 0.09
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.43
Quick Ratio 0.43
Altman-Z 1.19
F-Score6
WACC7.3%
ROIC/WACCN/A
Cap/Depr(3y)1981.94%
Cap/Depr(5y)5522.5%
Cap/Sales(3y)2080.11%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)101.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.56%
EPS Next Y-88.67%
EPS Next 2Y8.03%
EPS Next 3Y-4.65%
EPS Next 5YN/A
Revenue 1Y (TTM)-79.76%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y214.13%
Revenue Next 5YN/A
EBIT growth 1Y98.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y126.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y132.19%
OCF growth 3YN/A
OCF growth 5YN/A